EA200901621A1 - Индукция толерогенного фенотипа у зрелых дендритных клеток - Google Patents

Индукция толерогенного фенотипа у зрелых дендритных клеток

Info

Publication number
EA200901621A1
EA200901621A1 EA200901621A EA200901621A EA200901621A1 EA 200901621 A1 EA200901621 A1 EA 200901621A1 EA 200901621 A EA200901621 A EA 200901621A EA 200901621 A EA200901621 A EA 200901621A EA 200901621 A1 EA200901621 A1 EA 200901621A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dendritic cells
induction
mature dendritic
tolerogenic phenotype
tolerogenic
Prior art date
Application number
EA200901621A
Other languages
English (en)
Inventor
Хосе М. Карбаллидо-Эррера
Ян Э. Де-Врис
Ульф Кортхойер
Мария-Грация Ронкароло
Сильвия-Адриана Грегори
Original Assignee
Новартис Аг
Фондационе Чентро Сан Раффаэле Дель Монте Табор
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг, Фондационе Чентро Сан Раффаэле Дель Монте Табор filed Critical Новартис Аг
Publication of EA200901621A1 publication Critical patent/EA200901621A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

В заявке описано применение CD45-связывающей молекулы для модуляции функции дендритных клеток. В частности, в заявке описано применение CD45-связывающей молекулы для индукции толерогенных дендритных клеток, которые можно применять для лечения заболеваний или нарушений, таких как аутоиммунное заболевание, отторжение трансплантата.
EA200901621A 2007-06-05 2008-06-03 Индукция толерогенного фенотипа у зрелых дендритных клеток EA200901621A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07109672 2007-06-05
PCT/EP2008/056851 WO2008148761A1 (en) 2007-06-05 2008-06-03 Induction of tolerogenic phenotype in mature dendritic cells

Publications (1)

Publication Number Publication Date
EA200901621A1 true EA200901621A1 (ru) 2010-06-30

Family

ID=39721982

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200901621A EA200901621A1 (ru) 2007-06-05 2008-06-03 Индукция толерогенного фенотипа у зрелых дендритных клеток

Country Status (17)

Country Link
US (1) US20100183602A1 (ru)
EP (1) EP2160410A1 (ru)
JP (1) JP2010529078A (ru)
KR (1) KR20100035643A (ru)
CN (1) CN101687928A (ru)
AU (1) AU2008258646A1 (ru)
BR (1) BRPI0812205A2 (ru)
CA (1) CA2689570A1 (ru)
CL (1) CL2008001620A1 (ru)
EA (1) EA200901621A1 (ru)
IL (1) IL202230A0 (ru)
MA (1) MA31667B1 (ru)
MX (1) MX2009013220A (ru)
TN (1) TN2009000494A1 (ru)
TW (1) TW200907061A (ru)
WO (1) WO2008148761A1 (ru)
ZA (1) ZA200908089B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2347775T1 (sl) 2005-12-13 2020-10-30 President And Fellows Of Harvard College Ogrodja za celično transplantacijo
US9770535B2 (en) 2007-06-21 2017-09-26 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
CA2715460C (en) 2008-02-13 2020-02-18 President And Fellows Of Harvard College Continuous cell programming devices
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
EP2461828B1 (en) 2009-07-31 2017-06-21 President and Fellows of Harvard College Programming of cells for tolerogenic therapies
EP2305277A1 (en) * 2009-09-18 2011-04-06 Forskarpatent I Syd AB Use of tolerogenic dendritic cells in treatment and prevention of atherosclerosis
ES2773858T3 (es) 2010-10-06 2020-07-15 Harvard College Hidrogeles formadores de poros inyectables para terapias celulares basadas en materiales
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
WO2012149358A1 (en) 2011-04-28 2012-11-01 President And Fellows Of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
US9289477B2 (en) 2011-04-29 2016-03-22 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers to reduce cytotoxic T lymphocyte responses
US9486512B2 (en) 2011-06-03 2016-11-08 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
WO2013036293A1 (en) * 2011-09-06 2013-03-14 Selecta Biosciences, Inc. Dendritic cell subsets for generating induced tolerogenic dendritic cells and related compositions and methods
ES2773895T3 (es) 2012-04-16 2020-07-15 Harvard College Composiciones de sílice mesoporosa para modular las respuestas inmunitarias
EA201592106A3 (ru) 2013-05-03 2016-08-31 Селекта Байосайенсиз, Инк. Локальное сопутствующее введение толерогенных синтетических наноносителей для снижения гиперчувствительности типа i и гиперчувствительности типа iv
US10682400B2 (en) 2014-04-30 2020-06-16 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
WO2016037163A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses
US11786457B2 (en) 2015-01-30 2023-10-17 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
JP7094533B2 (ja) 2015-04-10 2022-07-04 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫細胞捕捉デバイスおよびその製造および使用方法
CN115487351A (zh) 2016-02-06 2022-12-20 哈佛学院校长同事会 重塑造血巢以重建免疫
JP2019522486A (ja) 2016-07-13 2019-08-15 プレジデント アンド フェローズ オブ ハーバード カレッジ 抗原提示細胞模倣足場およびそれを作製および使用するための方法
BR112019018748A2 (pt) 2017-03-11 2020-04-07 Selecta Biosciences Inc métodos e composições relacionados ao tratamento combinado com anti-inflamatórios e nanocarreadores sintéticos compreendendo um imunossupressor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0103389D0 (en) * 2001-02-12 2001-03-28 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
MA31667B1 (fr) 2010-09-01
IL202230A0 (en) 2010-06-16
BRPI0812205A2 (pt) 2014-11-25
CN101687928A (zh) 2010-03-31
TN2009000494A1 (en) 2011-03-31
CL2008001620A1 (es) 2009-02-20
TW200907061A (en) 2009-02-16
MX2009013220A (es) 2010-04-09
KR20100035643A (ko) 2010-04-05
US20100183602A1 (en) 2010-07-22
WO2008148761A1 (en) 2008-12-11
CA2689570A1 (en) 2008-12-11
ZA200908089B (en) 2010-07-28
EP2160410A1 (en) 2010-03-10
AU2008258646A1 (en) 2008-12-11
JP2010529078A (ja) 2010-08-26

Similar Documents

Publication Publication Date Title
EA200901621A1 (ru) Индукция толерогенного фенотипа у зрелых дендритных клеток
UA115402C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
MY163275A (en) Ibat inhibitors for the treatment of liver diseases
MX2009009283A (es) Anticuerpos anti-interleuquina -23r de ingenieria.
MX366318B (es) Derivados de aminas heterocíclicas que inhiben la transducción de señal mediana por cinasa asociada con el receptor de interleucina-1.
MX2010008688A (es) Anticuerpos anti-receptor de linfopoyetina estromal timica procesados por ingenieria.
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201000844A1 (ru) Связывающие wise агенты и эпитопы
EA201400579A1 (ru) Антитела к il-36r
MX2009006471A (es) Anticuerpo anti especifico de linfopoyetina estromal timica de diseño.
MA32190B1 (fr) Anticorps dirigés contre l'angiopoïétine 1 et l'angiopoïétine 2 et leur utilisation
MX2012011840A (es) Estructuras multimericas especificas para ligado inductor de apoptosis relacionada con el factor de necrosis tumoral r2 (trial).
MY172372A (en) Compositions and methods for lowering triglycerides
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MA33939B1 (fr) 5-alcynyl-pyrimidines
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
DK3135672T3 (da) Sammensætninger og fremgangsmåder til behandling af alkoholforbrugslidelser, smerter og andre sygdomme
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MX2012012928A (es) Composiciones y metodos de uso para anticuerpos terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
WO2010009478A3 (en) Compositions and methods for treating disorders associated with overweight animals
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2009009190A (es) Compuestos heterociclicos, composiciones que los comprenden y metodos que los emplean.
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
MX2014014443A (es) Agentes de ligacion a tlr3.
EA201000864A1 (ru) Фенилоксетанильные производные